The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of escalating doses of neoadjuvant atezolizumab for patients with non-metastatic urothelial carcinoma ineligible for cisplatin-based neoadjuvant chemotherapy.
 
Vadim S Koshkin
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Dendreon; Gerson Lehrman Group; Guidepoint Global; Janssen; Pfizer/EMD Serono; Seattle Genetics/Astellas
Speakers' Bureau - Seattle Genetics/Astellas
Research Funding - Clovis Oncology; Endocyte; Nektar
Travel, Accommodations, Expenses - AstraZeneca; Janssen
 
Divya Natesan
No Relationships to Disclose
 
Li Zhang
Consulting or Advisory Role - Dendreon; Fortis; Unity Biotechnology
Travel, Accommodations, Expenses - Dendreon; Dendreon; Dendreon
 
David Yoonsuk Oh
Consulting or Advisory Role - Maze Therapeutics
Research Funding - Merck (Inst); PACT Pharma (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Inventor on patent claiming methods for the use and optimization of cytotoxic CD4+ T cell therapy for cancer.; Inventor on patent claiming methods to identify patients who will respond to or experience toxicity with cancer immunotherapies based on T cell receptor sequencing.
Travel, Accommodations, Expenses - Roche/Genentech
 
Sima P. Porten
Honoraria - photocure
Consulting or Advisory Role - Bristol-Myers Squibb; KDx Diagnostics; Photocure
Research Funding - Photocure (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Maxwell Meng
No Relationships to Disclose
 
Raj Pruthi
No Relationships to Disclose
 
Rahul Raj Aggarwal
Honoraria - Clovis Oncology
Consulting or Advisory Role - AstraZeneca; Dendreon; Janssen
Research Funding - Abbvie (Inst); Amgen (Inst); Cancer Targeted Technology (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Xynomic Pharma
 
Eric Jay Small
Stock and Other Ownership Interests - Fortis; Harpoon Therapeutics
Honoraria - Janssen
Consulting or Advisory Role - Beigene; Fortis; Janssen Oncology; Teon Therapeutics; Tolero Pharmaceuticals
Research Funding - Janssen (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Janssen
 
Lawrence Fong
Consulting or Advisory Role - Atreca; BioAtla; Bolt Biotherapeutics; Nutcracker Therapeutics, Inc.; TeneoBio
Research Funding - Abbvie (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Terence W. Friedlander
Leadership - Med BioGene
Honoraria - AstraZeneca/MedImmune; EMD Serono; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Consulting or Advisory Role - Abbvie; Abbvie; AstraZeneca; Dava Oncology; Dendreon; Foundation Medicine; Janssen; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Janssen; Neon Therapeutics (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Genentech/Roche; Jounce Therapeutics